Comment on ‘‘Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs’’

Autor:	Urtasun, Martin A., Prozzi, Guillermo Rafael, Marín, Gustavo Horacio, Buschiazzo, Héctor Omar, Cañás, Martín, Dorati, Cristian Matías, Mordujovich, Perla
Jazyk:	angličtina
Rok vydání:	2017
Předmět:	Cardiovascular safety Celecoxib organic chemicals Farmacología Ciencias Médicas lipids (amino acids peptides and proteins)
Popis:	In a recent issue of the American Journal of Cardiovascular Drugs, Thomas et al. analyzed the cardiovascular safety of cyclo-oxygenase (COX)-2 inhibitors (coxibs). In the Recommendations section of the paper, the authors stated that, based on the results of the PRECISION (Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen) trial, celecoxib at moderate doses is not inferior to ibuprofen or naproxen in terms of cardiovascular safety. The PRECISION investigators seem to imply that celecoxib is a ‘cardiovascular safe’ drug, and we would like to challenge this statement with a more detailed analysis of the PRECISION trial. Facultad de Ciencias Médicas
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=od______1329::ec707ecd4c41bdae86406c84b209a2e2 http://sedici.unlp.edu.ar/handle/10915/104914 Zobrazit plný text záznamu